Morgan Stanley Investment Funds Emerging Markets Equity Fund has sold a 0.58% stake in Gland Pharma via open market transactions. The sell-off consisted of 9.6 lakh shares at a weighted average price of INR9,306.69 ($124.51). Majority promoter-owned Gland Pharma is injectables-focused and operates a business to business model. It manufacturers a range of injections, including vials, ampoules, pre-filled syringes, lyophilised vials, oncology and ophthalmic solutions. The company reported a 56% decline in Q4 profit in May 2021, dragged down by weak domestic and international sales.